A detailed history of Engineers Gate Manager LP transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Engineers Gate Manager LP holds 12,707 shares of PTGX stock, worth $571,052. This represents 0.01% of its overall portfolio holdings.

Number of Shares
12,707
Previous 37,570 66.18%
Holding current value
$571,052
Previous $1.09 Million 59.48%
% of portfolio
0.01%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$24.66 - $34.8 $613,121 - $865,232
-24,863 Reduced 66.18%
12,707 $440,000
Q1 2024

May 15, 2024

BUY
$21.79 - $32.15 $545,795 - $805,293
25,048 Added 200.03%
37,570 $1.09 Million
Q4 2023

Feb 14, 2024

SELL
$14.05 - $23.44 $187,314 - $312,502
-13,332 Reduced 51.57%
12,522 $287,000
Q3 2023

Nov 14, 2023

BUY
$16.68 - $23.66 $431,244 - $611,705
25,854 New
25,854 $431,000
Q1 2023

May 15, 2023

SELL
$10.78 - $25.38 $63,709 - $149,995
-5,910 Reduced 38.91%
9,278 $213,000
Q4 2022

Feb 14, 2023

BUY
$7.36 - $11.17 $111,783 - $169,649
15,188 New
15,188 $165,000
Q2 2022

Aug 15, 2022

SELL
$7.06 - $25.52 $320,382 - $1.16 Million
-45,380 Reduced 79.95%
11,383 $90,000
Q1 2022

May 16, 2022

BUY
$23.34 - $36.08 $1.32 Million - $2.05 Million
56,763 New
56,763 $1.34 Million
Q3 2021

Nov 15, 2021

SELL
$12.95 - $49.69 $60,994 - $234,039
-4,710 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$25.57 - $44.88 $120,434 - $211,384
4,710 New
4,710 $211,000
Q1 2021

May 17, 2021

SELL
$19.02 - $31.15 $247,830 - $405,884
-13,030 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$18.49 - $25.13 $240,924 - $327,443
13,030 New
13,030 $263,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.21B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.